| NCT ID | NCT06068335 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Central Florida |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-10-18 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-10-18 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
Eligibility Criteria
Inclusion Criteria: * Participants must be at least 18 years of age * no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma. Exclusion Criteria: * Pregnant women and prisoners will be excluded from the study. * Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.
Contact & Investigator
Justine T Tigno-Aranjuez, PhD
PRINCIPAL INVESTIGATOR
University of Central Florida
Frequently Asked Questions
Who can join the NCT06068335 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06068335 currently recruiting?
Yes, NCT06068335 is actively recruiting participants. Contact the research team at amoy.fraser@ucf.edu for enrollment information.
Where is the NCT06068335 trial being conducted?
This trial is being conducted at Orlando, United States.
Who is sponsoring the NCT06068335 clinical trial?
NCT06068335 is sponsored by University of Central Florida. The principal investigator is Justine T Tigno-Aranjuez, PhD at University of Central Florida. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.